Treatment outcomes of Black and White AYA patients with AML
| All AYA patients (aged 18-39 y) . | ||||
|---|---|---|---|---|
| Endpoint . | Black patients (n = 89) . | White patients (n = 566) . | P∗ . | OR/HR (95% CI) . |
| Early death, n (%)† | 10 (11) | 14 (2) | <.001 | 7.50 (1.91, 29.51)‡ |
| CR, n (%)† | 65 (73) | 463 (82) | .06 | 1.28 (0.83, 1.37) |
| n = 61‡ | n = 378‡ | |||
| DFS | .25 | 0.90 (0.58, 1.47) | ||
| Median, y | 1.2 | 1.4 | ||
| Disease-free at 5 y, % (95% CI) | 32% (21-44) | 40% (35-45) | ||
| n = 85‡ | n = 481‡ | |||
| OS | .002 | 0.67 (0.47, 0.96) | ||
| Median, y | 1.5 | 3.1 | ||
| Alive at 5 y, % (95% CI) | 32% (23-42) | 46% (41-50) | ||
| All AYA patients (aged 18-39 y) . | ||||
|---|---|---|---|---|
| Endpoint . | Black patients (n = 89) . | White patients (n = 566) . | P∗ . | OR/HR (95% CI) . |
| Early death, n (%)† | 10 (11) | 14 (2) | <.001 | 7.50 (1.91, 29.51)‡ |
| CR, n (%)† | 65 (73) | 463 (82) | .06 | 1.28 (0.83, 1.37) |
| n = 61‡ | n = 378‡ | |||
| DFS | .25 | 0.90 (0.58, 1.47) | ||
| Median, y | 1.2 | 1.4 | ||
| Disease-free at 5 y, % (95% CI) | 32% (21-44) | 40% (35-45) | ||
| n = 85‡ | n = 481‡ | |||
| OS | .002 | 0.67 (0.47, 0.96) | ||
| Median, y | 1.5 | 3.1 | ||
| Alive at 5 y, % (95% CI) | 32% (23-42) | 46% (41-50) | ||
| Patients aged 18-29 y . | ||||
|---|---|---|---|---|
| Endpoint . | Black patients (n = 44) . | White patients (n = 252) . | P∗ . | OR/HR (95% CI) . |
| Early death, n (%)† | 7 (16) | 7 (3) | .002 | 16.23 (2.45, 107.72)‡ |
| CR, n (%)† | 29 (66) | 208 (83) | .01 | 3.17 (1.03, 9.80) |
| n = 27§ | n = 168§ | |||
| DFS | .16 | 0.96 (0.49, 1.89) | ||
| Median, y | 1.2 | 1.8 | ||
| Disease-free at 5 y, % (95% CI) | 24% (10-42) | 42% (34-49) | ||
| n = 42§ | n = 212§ | |||
| OS | <.001 | 0.48 (0.28, 0.81) | ||
| Median, y | 1.3 | 10.2 | ||
| Alive at 5 y, % (95% CI) | 22% (11-36) | 51% (44-57) | ||
| Patients aged 18-29 y . | ||||
|---|---|---|---|---|
| Endpoint . | Black patients (n = 44) . | White patients (n = 252) . | P∗ . | OR/HR (95% CI) . |
| Early death, n (%)† | 7 (16) | 7 (3) | .002 | 16.23 (2.45, 107.72)‡ |
| CR, n (%)† | 29 (66) | 208 (83) | .01 | 3.17 (1.03, 9.80) |
| n = 27§ | n = 168§ | |||
| DFS | .16 | 0.96 (0.49, 1.89) | ||
| Median, y | 1.2 | 1.8 | ||
| Disease-free at 5 y, % (95% CI) | 24% (10-42) | 42% (34-49) | ||
| n = 42§ | n = 212§ | |||
| OS | <.001 | 0.48 (0.28, 0.81) | ||
| Median, y | 1.3 | 10.2 | ||
| Alive at 5 y, % (95% CI) | 22% (11-36) | 51% (44-57) | ||
| Patients aged 30-39 y . | ||||
|---|---|---|---|---|
| Endpoint . | Black patients (n = 45) . | White patients (n = 214) . | P∗ . | OR/HR (95% CI) . |
| Early death, n (%)† | 3 (7) | 7 (2) | .12 | 2.83 (0.28, 28.70)‡ |
| CR, n (%)† | 36 (80) | 255 (81) | .84 | 0.54 (0.15, 1.96) |
| n = 34§ | n = 210§ | |||
| DFS | .73 | 0.81 (0.46. 1.44) | ||
| Median, y | 1.2 | 1.4 | ||
| Disease-free at 5 y, % (95% CI) | 8% (22-54) | 39% (32-45) | ||
| n = 43§ | n = 269§ | |||
| OS | .49 | 0.87 (0.53, 1.44) | ||
| Median, y | 2.2 | 2.2 | ||
| Alive at 5 y, % (95% CI) | 42% (27-56) | 42% (36-48) | ||
| Patients aged 30-39 y . | ||||
|---|---|---|---|---|
| Endpoint . | Black patients (n = 45) . | White patients (n = 214) . | P∗ . | OR/HR (95% CI) . |
| Early death, n (%)† | 3 (7) | 7 (2) | .12 | 2.83 (0.28, 28.70)‡ |
| CR, n (%)† | 36 (80) | 255 (81) | .84 | 0.54 (0.15, 1.96) |
| n = 34§ | n = 210§ | |||
| DFS | .73 | 0.81 (0.46. 1.44) | ||
| Median, y | 1.2 | 1.4 | ||
| Disease-free at 5 y, % (95% CI) | 8% (22-54) | 39% (32-45) | ||
| n = 43§ | n = 269§ | |||
| OS | .49 | 0.87 (0.53, 1.44) | ||
| Median, y | 2.2 | 2.2 | ||
| Alive at 5 y, % (95% CI) | 42% (27-56) | 42% (36-48) | ||
CI, confidence interval; HR, hazard ratio; OR, odds ratio.
P values for categorical variables are from Fisher’s exact test; P values for the time to event variables are from the log-rank test.
For early death and CR analyses, the denominator included patients who received an allogeneic HSCT in first CR.
Because of a wide CI, the result should be interpreted with caution.
DFS and OS analyses exclude patients who received an allogeneic HSCT in first CR.